PO.CL05.13 · 临床研究

用于评估靶向cGAS-STING轴的免疫疗法的新型临床前免疫功能健全小鼠模型

Novel preclinical immunocompetent mouse model for assessment of immunotherapies targeting cGAS-STING axis

海报缩略图:用于评估靶向cGAS-STING轴的免疫疗法的新型临床前免疫功能健全小鼠模型
编号 6699 展板 10 时间 4/21 02:00–05:00 区域 Section 49 主讲 Fabiane Sonego, MS;PhD
分会场 Vaccines and Other Immunomodulatory Agents
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Angela Pappalardo, Philippe De La Rochere, Patricia Isnard-Petit, Gaëlle H. Martin, Fabiane Sonego, Kader Thiam

genOway, Lyon, France

摘要 Abstract

中文摘要
环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子(cGAS-STING)信号轴代表一条关键的免疫刺激通路,是肿瘤学中一个有吸引力的药理学靶点。其在肿瘤微环境内的激活促进肿瘤相关抗原的交叉启动,并增强效应T淋巴细胞的浸润。由于其强效的抗肿瘤活性,cGAS-STING通路为癌症疫苗、抗体-药物偶联物等免疫治疗策略以及针对病毒驱动型恶性肿瘤的干预措施的开发提供了重大前景。然而,由于人与小鼠cGAS和STING之间存在物种特异性差异,将临床前发现转化为临床应用一直具有挑战性。此前已报道过一种仅表达人STING的模型,并证实其是研究STING激动剂在不同肿瘤类型中活性的宝贵工具。在此,我们报道一种同时表达人cGAS和人STING的免疫功能健全小鼠模型(genO-hcGAS-hSTING)。与WT小鼠相比,cGAS和STING的人源化并未改变脾脏、血液和骨髓中的免疫细胞组成。通过Western Blot在脑和肺中确认了人cGAS的表达,而通过流式细胞术在脾脏和血液的免疫细胞中确认了hSTING的表达。通过用非人特异性cGAS激动剂G3-YSD激活脾细胞来研究cGAS的功能,其诱导了IFN-alpha、IFN-gamma和TNF-alpha的分泌。同样,还通过用diABZi和DMXAA激活脾细胞来研究STING的功能。diABZi同时激活人和小鼠STING,而DMXAA特异性激活小鼠STING。事实上,diABZi在来自WT和genO-hcGAS-hSTING小鼠的细胞中均诱导IFN-beta、CXCL10和IL-6的分泌,而DMXAA仅在WT中诱导细胞因子分泌。这些数据表明,genO-hcGAS-hSTING小鼠中表达的人STING具有功能,而这些小鼠中不再表达小鼠STING。这些人源化模型为评估靶向人cGAS和STING通路的化合物的疗效和特异性提供了宝贵工具,有可能简化药物发现并增进我们对人类健康与疾病中固有免疫应答的理解。
查看英文原文 English abstract
The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling axis represents a pivotal immunostimulatory pathway and an attractive pharmacological target in oncology. Its activation within the tumor microenvironment promotes cross-priming of tumor-associated antigens and enhances infiltration of effector T lymphocytes. Owing to its potent antitumor activity, the cGAS-STING pathway offers significant promise for the development of cancer vaccines, immunotherapeutic strategies such as antibody-drug conjugates, and interventions against virus-driven malignancies. However, translating preclinical findings to clinical applications has been challenging due to species-specific differences between human and mouse cGAS and STING. A model expressing human STING only has been previously reported and showed to be a valuable tool to investigate the activity of STING agonist in different tumor types. Herein, we report an immunocompetent mouse model expressing both human cGAS and human STING (genO-hcGAS-hSTING). Humanization of cGAS and STING did not alter immune cell composition in the spleen, blood and bone marrow when compared to WT mice. Expression of human cGAS has been confirmed in brain and lung by Western Blot, while hSTING expression was confirmed in immune cells in the spleen and blood by flow cytometry. Functionality of cGAS was investigated through activation of splenocytes with the non-human-specific cGAS agonist G3-YSD, which induced IFN-alpha, IFN-gamma, and TNF-alpha secretion. Similarly, functionality of STING has also been investigated by activating splenocytes with diABZi and DMXAA. While diABZi activates both human and mouse STING, DMXAA activates specifically mouse STING. Indeed, diABZi induces the secretion of IFN-beta, CXCL10, and IL-6 in cells from both WT genO-hcGAS-hSTING mice, wherein DMXAA induced cytokine secretion in WT only. These data indicate that human STING expressed in genO-hcGAS-hSTING mice is functional and mouse STING is no longer expressed in these mice. These humanized models provide valuable tools for assessing the efficacy and specificity of compounds targeting human cGAS and STING pathways, potentially streamlining drug discovery and enhancing our understanding of innate immune responses in human health and disease.
利益披露 Disclosure
A. Pappalardo, genOway Employment, Stock, Stock Option. P. De La Rochere, genOway Employment, Stock, Stock Option. P. Isnard-Petit, genOway Employment, Stock, Stock Option. G. H. Martin, genOway Employment, Stock, Stock Option. F. Sonego, genOway Employment, Stock, Stock Option. K. Thiam, genOway Employment, g., Board of Directors, non-salaried role), Stock, Stock Option.

← 返回 AACR 2026 检索